알츠하이머 치매 치료제

Alzheimer’s Disease: Clinical Trials and Future Perspectives

Alzheimer’s disease is increasingly common in elderly population with a large socioeconomic burden. Current available drugs for Alzheimer’s disease are acetylcholinesterase inhibitors and N-methyl-D-aspartate receptor antagonist. Much effort is directed towards not just symptomatic treatments but disease-modifying treatments. Several drugs with differing targets and mechanisms of action are under development for the treatment of Alzheimer’s disease. Phase Ⅲ trials of dimebon, Ginkgo biloba, non-steroidal anti-inflammatory drugs, phenserine, statins, semagacestat, tarenflurbil, tramiprosate, valproate, xaliproden have been completed without demonstrating adequate efficacy. Encouraging results would be expected from ongoing phase Ⅲ trials of bapineuzumab and solanezumab. The clinical trials for the disease-modifying treatment of Alzheimer’s disease have resulted in both promise and disappointment.